相关实验视频
Updated: Jul 6, 2025

09:11
Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
6.6K
通过素脱乙酶抑制的代谢重编程优先针对NRF2-激活瘤
Dimitris Karagiannis1, Warren Wu2, Albert Li3
1Department of Genetics and Development, Columbia University Irving Medical Center, New York, NY 10032, USA.
Cell reports
|January 2, 2024
概括
肺腺癌与NRF2激活变得易受组织素脱乙酶 (HDAC) 抑制剂. 这是因为抑制HDAC会破坏NRF2-活性癌细胞存活所必需的代谢途径.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 代谢和染色体信号相互作用对癌症进展至关重要.
- 在肺腺癌 (LUAD) 中异常的NRF2通路激活驱动了侵袭性和化疗抵抗性疾病.
- 瘤代谢重编程产生染色体脆弱性的机制尚不清楚.
研究的目的:
- 调查NRF2激活是否使LUAD对I类组胺脱乙酶 (HDAC) 抑制产生敏感性.
- 阐明关联NRF2,HDAC抑制和代谢脆弱性的潜在分子机制.
- 探索重新利用HDAC抑制剂对NRF2-活性固体瘤的治疗潜力.
主要方法:
- 在LUAD细胞中以染色体为重点的CRISPR查.
- 在体外,体内 (小鼠模型) 和患者衍生的异种移植研究.
- 综合表观基因组,转录基因组和代谢基因组分析.
主要成果:
- 在LUAD中,NRF2激活赋予了对I类HDAC抑制的敏感性.
- 抑制HDAC会导致H4ac的再分配,降低代谢酶的调节.
- 在对NRF2-活性癌细胞至关重要的氨基酸和核酸合成途径中,代谢流量减少.
- 这种敏感性在细胞培养,小鼠模型和异种移植中是一致的.
结论:
- 激活NRF2会产生一种代谢依赖性,这种依赖性可以被HDAC抑制剂在LUAD中利用.
- 抑制HDAC会破坏重要的代谢途径,选择性地影响NRF2-活性癌细胞.
- 在固体瘤中,NRF2激活可以作为HDAC抑制剂治疗的预测生物标志物.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Electron Transport Chain: Complex I and II
13.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
13.5K
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
NF-κB-dependent Signaling Pathway
7.4K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.4K

